Naples-based biotechnology company Enveric Biosciences experienced a net loss attributable to stockholders of $3.2 million for the fourth quarter of 2024, according to an earnings report. This included a $1 million in net noncash expense, with a basic and diluted loss per share of $4.83, as compared to a net loss of $3.4 million, including $1.5 million in net noncash income, with a basic and diluted loss per share of $21.90 for the quarter of 2023. The company specializes in the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders.